Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Approach to Temperature Control in Cell Therapy Clinical Trial

Published: Wednesday, April 23, 2014
Last Updated: Wednesday, April 23, 2014
Bookmark and Share
CoolCell® cell freezing device and CoolBox™ ice-free cooling workstations chosen to support handling and processing of investigational cell therapy product in landmark clinical research trial.

BioCision, LLC has announced that several of the company’s products used to support temperature control, as well as processing and handling of cell therapy products, will be used in a Phase IIb clinical trial conducted by TxCell.

The trial will investigate the use of Ovasave®, an antigen-specific regulatory T (Ag-Treg) autologous cell-based immunotherapy for the treatment of patients with moderate to severe refractory Crohn’s disease.

In the Ovasave® Phase IIb trial, TxCell, which specializes in developing cell-based therapies for chronic inflammatory disease, will use the BioCision CoolCell® passive cell freezing device as the method for freezing Ag-Treg cells.

In previous Ovasave® trials, TxCell used electronic programmable controlled-rate freezers (CRF) to manage the cell freezing temperature, however, the CoolCell® containers will be used for this trial as they provide a cost-effective alternative to the CRF, with the same freezing efficiency and post-thaw outcomes, while also being significantly less expensive to deploy and maintain.

Regulatory T cells are extremely sensitive and changes in efficacy can occur with variations in temperature and handling regimes. TxCell determined that the BioCision products are suitable for use in their authorized Class B manufacturing facility and, therefore, also chose the BioCision CoolBox™ ice-free cooling workstations to ensure standardized and reproducible handling of the cells during manufacturing. The proprietary CoolBox ice-free cooling technology enables asceptic workflow and uniform sample handling, minimizing risk of temperature fluctuation and contamination.

“BioCision products can help researchers in cellular and regenerative medicine achieve the highest possible standards in sample processing and handling, especially as it relates to standardizing the cell cryopreservation workflow,” said Rolf Ehrhardt, MD, PhD, BioCision CEO. “We are pleased that TxCell has selected BioCision products for the Ovasave® Phase IIb trial, and we look forward to working them and other leaders in regenerative medicine and cell therapy research to advance these promising therapies.”

In October 2012, TxCell has announced publication of complete results of the Phase I/II CATS1 study and presented data from a one-year extension of the study supporting the long term tolerability of Ovasave® in the treatment of patients with moderate to severe refractory Crohn’s disease. The development of Ovasave® involves a proprietary manufacturing process where Ag-Treg cells are isolated from the whole blood of the patient and are then expanded ex vivo before reinjection into that same patient.

“As we advance our promising clinical research program for Ovasave® to a Phase IIb trial, the BioCision product portfolio and technology platform present the ideal range of capabilities and quality standards necessary to help us maintain the essential levels of standardization and control we need to be successful,” said TxCell Arnaud Foussat, Vice President Research and New Products at TxCell.

TxCell will present additional details on the use of CoolCell® containers for cell freezing on April 24, 2014 during Poster Session 1 at the 20th Annual Meeting of the International Society of Cellular Therapy in Paris. The abstract is titled, “Use of a low-cost passive freezing device in the effective cryopreservation and recovery of human regulatory T-cells for use in a cell therapy trial.”

The authors evaluated CoolCell containers as an alternative to the classical controlled-rate freezer, resulting in a new standardized method of cell therapy product cryopreservation and marking an important milestone in the ultimate use of cell therapy in the clinic.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BioCision Announces Two New U.S. Patents for Thermo-Conductive Products
New patents awarded for CoolSink® Plate Modules and ThermalTray™ Platforms.
Thursday, June 20, 2013
Scientific News
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
New Strategy for Combating Adenoviruses
Using an animal model they developed, Saint Louis University and Utah State university researchers have identified a strategy that could keep a common group of viruses called adenoviruses from replicating and causing sickness in humans.
Major Advance Toward More Effective, Long-Lasting Flu Vaccine
Collaboration shows vaccine candidate can produce powerful ‘broadly neutralizing antibodies’ in animal models.
Immune System: Help for Killer Cells
A study from the University of Bonn may show the way to more effective vaccines.
Protein Found to Control Inflammatory Response
A new Northwestern Medicine study shows that a protein called POP1 prevents severe inflammation and, potentially, diseases caused by excessive inflammatory responses.
A Leap Forward in Vaccinating Against HIV
A team of scientists has developed an experimental vaccine candidate that successfully stimulates the immune system activity in animal models necessary to stop HIV infection.
MRI Scanners Can Steer Therapeutics to Specific Target Sites
Scientists from the University of Sheffield have discovered MRI scanners, normally used to produce images, can steer cell-based, tumour busting therapies to specific target sites in the body.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Team Finds Early Inflammatory Response Paralyzes T Cells
Findings could have enormous implications for immunotherapy, autoimmune disorders, transplants and other aspects of immunity.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!